German biotech BioNTech (Nasdaq: BNTX), which shot into the limelight with the development of the most successful COVID-19 vaccine, Comirnaty, has reported financial results for the three months ended ...
Chris Shibutani has given his Hold rating due to a combination of factors including BioNTech SE’s recent financial performance and future prospects. The company’s first-quarter earnings for 2024 ...
Welcome to BioNTech's First Quarter 2024 Earnings Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations. Please go ahead.